Sandoz, the world's second-largest generic drugs company and a unit of Swiss drug maker Novartis has decided to shut its active pharmaceutical ingredients or API development facility near Mumbai. A Novartis spokesperson said in an e-mail to this writer that this was part of "recent project portfolio optimization within Sandoz Global Development." The spokesperson added … Continue reading Straws in the wind? Sandoz to shut API devt centre in India
Apothecurry 